Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AstraZeneca extends virtual neuroscience reach

This article was originally published in Scrip

Executive Summary

When AstraZeneca announced in February that neuroscience R&D would be a major target of a restructuring initiative there were concerns that it might exit the whole area ( , 2 February, 2012). To counter those fears, the company line was that it was deeply committed to neuroscience research but would take a more virtual approach that involves tapping into external expertise. As part of that strategy AstraZeneca signed its second and third deals on 12 July.



Related Companies